Development of a robotic cluster for automated and scalable cell therapy manufacturing
Alice Melocchi,Brigitte Schmittlein,Alexis L Jones,Yasmine Ainane,Ali Rizvi,Darius Chan,Elaine Dickey,Kelsey Pool,Kenny Harsono,Dorothy Szymkiewicz,Umberto Scarfogliero,Varun Bhatia,Amlesh Sivanantham,Nadia Kreciglowa,Allison Hunter,Miguel Gomez,Adrian Tanner,Marco Uboldi,Arpit Batish,Joanna Balcerek,Mariella Kutova-Stoilova,Sreenivasan Paruthiyil,Luis A Acevedo,Rachel Stadnitskiy,Sabrina Carmichael,Holger Aulbach,Matthew Hewitt,Xavier De Mollerat Du Jeu,Benedetta di Robilant,Federico Parietti,Jonathan H Esensten
DOI: https://doi.org/10.1016/j.jcyt.2024.03.010
IF: 6.196
Cytotherapy
Abstract:Background aims: The production of commercial autologous cell therapies such as chimeric antigen receptor T cells requires complex manual manufacturing processes. Skilled labor costs and challenges in manufacturing scale-out have contributed to high prices for these products. Methods: We present a robotic system that uses industry-standard cell therapy manufacturing equipment to automate the steps involved in cell therapy manufacturing. The robotic cluster consists of a robotic arm and customized modules, allowing the robot to manipulate a variety of standard cell therapy instruments and materials such as incubators, bioreactors, and reagent bags. This system enables existing manual manufacturing processes to be rapidly adapted to robotic manufacturing, without having to adopt a completely new technology platform. Proof-of-concept for the robotic cluster's expansion module was demonstrated by expanding human CD8+ T cells. Results: The robotic cultures showed comparable cell yields, viability, and identity to those manually performed. In addition, the robotic system was able to maintain culture sterility. Conclusions: Such modular robotic solutions may support scale-up and scale-out of cell therapies that are developed using classical manual methods in academic laboratories and biotechnology companies. This approach offers a pathway for overcoming manufacturing challenges associated with manual processes, ultimately contributing to the broader accessibility and affordability for personalized immunotherapies.